Abstract Details

Title Increased Risk of Skin Cancer in Myasthenia Patients Treated with Azathioprine: A Nationwide Case-Control Study in Denmark

Topic Muscle Disease/Neuromuscular Junction

Presentation(s) P02 - (-)

Poster/Presentation
Number 192

Objective

Background BACKGROUND: Treatment of autoimmune MG frequently involves long-term exposure to immunosuppressants, including azathioprine. Use of azathioprine increases the risk of NMSC in organ recipients and probably also in patients with other autoimmune disorders, e.g., inflammatory bowel disease. No previous study has specifically investigated the risk of NMSC in MG patients treated with azathioprine.

Design/Methods DESIGN/METHODS: Case-control study based on Danish population-based registries. Cases were MG patients with a first time diagnosis of NMSC during 2004-2009. Age- and sex-matched controls were selected among MG patients with no history of cancer using incidence density sampling. Prior use of azathioprine in cases and controls was assessed through prescription records (1995-2009). We used conditional logistic regression to calculate odds ratios (OR) with 95% confidence intervals (CI) for skin cancer associated with a high cumulative dose (?150 g) or long-term use (?5 years) of azathioprine, adjusted for confounders.

Results RESULTS: We identified 30 cases and 360 matched controls. The prevalence of ever use of azathioprine varied between cases (53%) and controls (30%). Both high-cumulative dose (OR: 4.8; 95% CI: 1.7-13.6) and long-term (OR: 4.6; 95% CI: 1.7-12.6) use of azathioprine were associated with increased risk of NMSC compared with never use of the drug.

Conclusions CONCLUSIONS: Long-term use of azathioprine in MG patients increases the risk of NMSC.

Authors/Disclosures
Emil G. Pedersen, MD PRESENTER	No disclosure on file
Aaron Ellenbogen, DO	Dr. Ellenbogen has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for allergan. Dr. Ellenbogen has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for allergan. Dr. Ellenbogen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Ellenbogen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Supernus. Dr. Ellenbogen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for ipsen. Dr. Ellenbogen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Acorda.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Klaus Hansen, MD (Dept. Neurology 2082 Rigshospitalet)	No disclosure on file
	No disclosure on file
David Gaist, MD (Odense University Hospital)	Dr. Gaist has nothing to disclose.

��ɫ��

��ɫ��